Comment on "Vila-Córcoles et al., Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016."

Vaccine. 2021 Jul 5;39(30):4032-4033. doi: 10.1016/j.vaccine.2020.11.036.

Authors

Bradford D Gessner¹, Christian Theilacker², Cristina Méndez², Luis Jodar²

Affiliations

¹ Pfizer Vaccines, USA. Electronic address: Bradford.gessner@pfizer.com.
² Pfizer Vaccines, USA.

PMID: 34210396
DOI: 10.1016/j.vaccine.2020.11.036

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aged
Cohort Studies
Humans
Middle Aged
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Streptococcus pneumoniae
Treatment Outcome
Vaccination